Patents by Inventor Robert J Gillies
Robert J Gillies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167154Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: January 24, 2022Publication date: June 1, 2023Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Publication number: 20230038185Abstract: Two major treatment strategies employed in fighting non-small cell lung cancer (NSCLC) are tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The choice of strategy is based on heterogeneous biomarkers expressed by the lung tumor tissue. A major challenge for molecular testing of these biomarkers is the insufficiency of biopsy specimens from patients with advanced NSCLC. Disclosed herein is a method for predicting a response to immune-checkpoint blockade immunotherapy.Type: ApplicationFiled: December 7, 2020Publication date: February 9, 2023Inventors: Robert J. Gillies, Matthew B. Schabath, Wei MU
-
Patent number: 11458212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 9, 2019Date of Patent: October 4, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of the University of /ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Patent number: 11230568Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: June 24, 2019Date of Patent: January 25, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 11207429Abstract: Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.Type: GrantFiled: May 11, 2015Date of Patent: December 28, 2021Assignee: Arizona Board of Regents on behalf of the University of ArizonaInventors: Eugene A. Mash, Parastou Foroutan, Suryakiran Navath, Robert J. Gillies, Gary V. Martinez, David L. Morse
-
Patent number: 11077212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: August 24, 2011Date of Patent: August 3, 2021Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: David L. Morse, Robert J. Gillies, William Bradford Carter, Narges K. Tafreshi, Marilyn M. Bui, Steven A. Enkemann
-
Patent number: 10827945Abstract: Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple habitats within them. Disclosed herein are methods for analyzing these images to infer cellular and molecular structure in each of these habitats. The methods can involve spatially superimposing two or more radiological images of the tumor sufficient to define regional habitat variations in two or more ecological dynamics in the tumor, and comparing the habitat variations to one or more controls to predict the severity of the tumor.Type: GrantFiled: March 10, 2015Date of Patent: November 10, 2020Assignees: H. LEE. MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Robert J. Gillies, Robert A. Gatenby, Natarajan Raghunand, John Arrington, Olya Stringfield, Yoganand Balagurunathan, Dmitry B. Goldgof, Lawrence O. Hall
-
Publication number: 20200211180Abstract: An example method for diagnosing tumors in a subject by performing a quantitative analysis of a radiological image can include identifying a region of interest (ROI) in the radiological image, segmenting the ROI from the radiological image, identifying a tumor object in the segmented ROI and segmenting the tumor object from the segmented ROI. The method can also include extracting a plurality of quantitative features describing the segmented tumor object, and classifying the tumor object based on the extracted quantitative features. The quantitative features can include one or more texture-based features.Type: ApplicationFiled: August 5, 2019Publication date: July 2, 2020Inventors: Robert J. Gillies, Lawrence O. Hall, Dmitry B. Goldgof
-
Publication number: 20200164093Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: ApplicationFiled: September 9, 2019Publication date: May 28, 2020Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of The University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20200002376Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: June 24, 2019Publication date: January 2, 2020Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Patent number: 10406248Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 5, 2012Date of Patent: September 10, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board Of Regents on Behalf of the University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Patent number: 10373314Abstract: An example method for diagnosing tumors in a subject by performing a quantitative analysis of a radiological image can include identifying a region of interest (ROI) in the radiological image, segmenting the ROI from the radiological image, identifying a tumor object in the segmented ROI and segmenting the tumor object from the segmented ROI. The method can also include extracting a plurality of quantitative features describing the segmented tumor object, and classifying the tumor object based on the extracted quantitative features. The quantitative features can include one or more texture-based features.Type: GrantFiled: February 28, 2018Date of Patent: August 6, 2019Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Robert J. Gillies, Lawrence O. Hall, Dmitry B. Goldgof
-
Patent number: 10339653Abstract: An example method for analyzing quantitative information obtained from radiological images includes identifying a ROI or a VOI in a radiological image, segmenting the ROI or the VOI from the radiological image and extracting quantitative features that describe the ROI or the VOI. The method also includes creating a radiological image record including the quantitative features, imaging parameters of the radiological image and clinical parameters and storing the radiological image record in a data structure containing a plurality of radiological image records. In addition, the method includes receiving a request with the patient's radiological image or information related thereto, analyzing the data structure to determine a statistical relationship between the request and the radiological image records and generating a patient report with a diagnosis, a prognosis or a recommended treatment regimen for the patient's disease based on a result of analyzing the data structure.Type: GrantFiled: July 31, 2017Date of Patent: July 2, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., The Board of Trustees of the Leland Stanford Junior University, Stichting Maastricht Radiation Oncology ‘Maastro Clinic’Inventors: Robert J. Gillies, Steven A. Eschrich, Robert A. Gatenby, Philippe Lambin, Andreas L. A. J. Dekker, Sandy A. Napel, Sylvia K. Plevritis, Daniel L. Rubin
-
Patent number: 10339648Abstract: Disclosed are methods for quantitatively predicting the severity of a tumor in a subject. In some embodiments, the methods further comprise selecting a course of therapy for the subject. In some embodiments, the tumor comprises is non-small cell lung cancer.Type: GrantFiled: January 21, 2014Date of Patent: July 2, 2019Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Olya Stringfield, Robert J. Gillies
-
Patent number: 10329326Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: September 12, 2016Date of Patent: June 25, 2019Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 10258607Abstract: A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO3, 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), cholamine chloride, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). The method can further include the step of pretreating with one or more chemotherapeutic agents.Type: GrantFiled: May 24, 2012Date of Patent: April 16, 2019Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Robert J. Gillies, David L. Morse, Ariosto Siqueira Silva, Arig A. Ibrahim Hashim, Robert A. Gatenby, Gary Martinez
-
Patent number: 10183082Abstract: 18F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-mino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18F. The 18F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.Type: GrantFiled: September 9, 2015Date of Patent: January 22, 2019Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Haibin Tian, Robert J. Gillies
-
Publication number: 20180253843Abstract: An example method for diagnosing tumors in a subject by performing a quantitative analysis of a radiological image can include identifying a region of interest (ROI) in the radiological image, segmenting the ROI from the radiological image, identifying a tumor object in the segmented ROI and segmenting the tumor object from the segmented ROI. The method can also include extracting a plurality of quantitative features describing the segmented tumor object, and classifying the tumor object based on the extracted quantitative features. The quantitative features can include one or more texture-based features.Type: ApplicationFiled: February 28, 2018Publication date: September 6, 2018Inventors: Robert J. Gillies, Lawrence O. Hall, Dmitry B. Goldgof
-
Patent number: 9940709Abstract: An example method for diagnosing tumors in a subject by performing a quantitative analysis of a radiological image can include identifying a region of interest (ROI) in the radiological image, segmenting the ROI from the radiological image, identifying a tumor object in the segmented ROI and segmenting the tumor object from the segmented ROI. The method can also include extracting a plurality of quantitative features describing the segmented tumor object, and classifying the tumor object based on the extracted quantitative features. The quantitative features can include one or more texture-based features.Type: GrantFiled: October 10, 2014Date of Patent: April 10, 2018Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Robert J. Gillies, Lawrence O. Hall, Dmitry B. Goldgof
-
Publication number: 20170358079Abstract: An example method for analyzing quantitative information obtained from radiological images includes identifying a ROI or a VOI in a radiological image, segmenting the ROI or the VOI from the radiological image and extracting quantitative features that describe the ROI or the VOI. The method also includes creating a radiological image record including the quantitative features, imaging parameters of the radiological image and clinical parameters and storing the radiological image record in a data structure containing a plurality of radiological image records. In addition, the method includes receiving a request with the patient's radiological image or information related thereto, analyzing the data structure to determine a statistical relationship between the request and the radiological image records and generating a patient report with a diagnosis, a prognosis or a recommended treatment regimen for the patient's disease based on a result of analyzing the data structure.Type: ApplicationFiled: July 31, 2017Publication date: December 14, 2017Inventors: Robert J. Gillies, Steven A. Eschrich, Robert A. Gatenby, Philippe Lambin, Andreas L.A.J. Dekker, Sandy A. Napel, Sylvia K. Plevritis, Daniel L. Rubin